Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 721 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Clear all
Completed Phase 3 Interventional Results available

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

NCT00003901
View directory record Official record
Conditions
Lung Cancer
Interventions
immunohistochemistry staining method, biopsy, surgery
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
56
States / cities
Mobile, Alabama • Los Angeles, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00002550
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2013
U.S. locations
15
States / cities
Urbana, Illinois • Indianapolis, Indiana • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00005850
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Lung Cancer
Interventions
cisplatin, fluoxetine, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
42
States / cities
Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

NCT04350463
View directory record Official record
Conditions
Neoplasms
Interventions
CC-90011, Nivolumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • New York, New York • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Priming Immunotherapy in Advanced Disease With Radiation

NCT03313804
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Immune checkpoint inhibitor, Radiation Therapy
Drug · Radiation
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT01631552
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer
Interventions
Sacituzumab Govitecan-hziy (SG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
12
States / cities
Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 10, 2026, 9:46 PM EDT
Active, not recruiting Phase 1 Interventional

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

NCT02432963
View directory record Official record
Conditions
Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT00955305
View directory record Official record
Conditions
Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer, Bronchioloalveolar Lung Carcinoma
Interventions
Bevacizumab, Carboplatin, Cixutumumab, Paclitaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
165
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 122 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

NCT03590054
View directory record Official record
Conditions
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Abexinostat, Pembrolizumab
Drug · Biological
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00970684
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Nathan Pennell, MD, PhD
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 10, 2026, 9:46 PM EDT
Withdrawn Phase 3 Interventional

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00055887
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, efaproxiral, gemcitabine hydrochloride, paclitaxel, vinorelbine ditartrate, radiation therapy
Drug · Procedure
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
8
States / cities
Phoenix, Arizona • Coeur d'Alene, Idaho • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

NCT02328105
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Abraxane
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 10, 2026, 9:46 PM EDT
Recruiting Phase 3 Interventional

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer
Interventions
PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
226
States / cities
Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 164 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

NCT02264990
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
25
States / cities
Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

NCT01784640
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Hsp90 inhibitor AUY922, pemetrexed disodium, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 10, 2026, 9:46 PM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

NCT05479812
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
WTX-124, pembrolizumab
Drug
Lead sponsor
Werewolf Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional

Study of DF9001 in Patients With Advanced Solid Tumors

NCT05597839
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
DF9001, KEYTRUDA® (pembrolizumab)
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 10, 2026, 9:46 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

NCT07462377
View directory record Official record
Conditions
Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR
Interventions
EPI-326
Drug
Lead sponsor
EpiBiologics
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Los Angeles, California • East Brunswick, New Jersey • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00729612
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Greg Otterson
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

NCT01868022
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3052230, paclitaxel, carboplatin, docetaxel, pemetrexed, cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

NCT00087438
View directory record Official record
Conditions
Lung Cancer
Interventions
stereotactic body radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
2
States / cities
Rochester, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Rucaparib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
950
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 10, 2026, 9:46 PM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 10, 2026, 9:46 PM EDT